Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 6:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 38 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Atropine Clear all
Active, not recruiting Phase 2 Interventional

Myopia Control: a Comparison Study Between Atropine and MiSight

NCT05815784
View directory record Official record
Conditions
Myopia
Interventions
Atropine, MiSight contact lenses
Drug · Device
Lead sponsor
Ann & Robert H Lurie Children's Hospital of Chicago
Other
Eligibility
5 Years to 12 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 7, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

Trial Comparing Atropine to Atropine Plus a Plano Lens for the Sound Eye for Amblyopia in Children 3 to <7 Years Old

NCT00315302
View directory record Official record
Conditions
Amblyopia
Interventions
Atropine, Plano Lens
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
3 Years to 6 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Fullerton, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 18, 2016 · Synced Sep 7, 2026, 6:45 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Adverse Events Related to Low Dose Atropine

NCT05683535
View directory record Official record
Conditions
Myopia, Progressive
Interventions
Atropine Sulfate
Drug
Lead sponsor
Scripps Health
Other
Eligibility
Not listed
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Sep 7, 2026, 6:45 PM EDT
Terminated Not applicable Interventional Results available

Safety and Accuracy of Regadenoson-Atropine Stress Echocardiography in CAD

NCT00894179
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
regadenoson and atropine
Diagnostic Test
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years to 85 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 7, 2026, 6:45 PM EDT
Recruiting Phase 2 Interventional

Atropine Eye Drops for Watery Eyes (Excessive Tearing)

NCT07676981
View directory record Official record
Conditions
Epiphora
Interventions
Atropine ophthalmic solution
Drug
Lead sponsor
Rehan Ahmed
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
2
States / cities
Houston, Texas • Mesquite, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 7, 2026, 6:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Inhaled Atropine Sulfate in Healthy Adults

NCT00947596
View directory record Official record
Conditions
Organophosphorus Poisoning
Interventions
atropine sulfate
Drug
Lead sponsor
MicroDose Defense Products L.L.C.
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 11, 2010 · Synced Sep 7, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

Augmenting Atropine Treatment for Amblyopia in Children 3 to < 8 Years Old

NCT00944710
View directory record Official record
Conditions
Amblyopia
Interventions
Atropine, Plano lens
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
3 Years to 7 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Fullerton, California • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 7, 2026, 6:45 PM EDT
Completed Phase 4 Interventional Results available

Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly

NCT01951118
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Delirium, Dementia, Amnestic, Cognitive Disorders
Interventions
Donepezil
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 12, 2020 · Synced Sep 7, 2026, 6:45 PM EDT
Completed Phase 3 Interventional

Amblyopia (Lazy Eye) Treatment Study

NCT00001864
View directory record Official record
Conditions
Amblyopia, Anisometropia, Strabismus
Interventions
Atropine, Patch
Drug · Device
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
Not listed
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 7, 2026, 6:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Analysis of Atropine and Propranolol Induced Changes

NCT00251602
View directory record Official record
Conditions
Healthy
Interventions
Atropine, Propranolol, Normal Saline
Drug
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
21 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 5, 2012 · Synced Sep 7, 2026, 6:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sublingual vs IV Atropine Bioavailability Study

NCT04290039
View directory record Official record
Conditions
Toxic Effect of Organophosphate and Carbamate Insecticides
Interventions
Atropine Sulfate Ophthalmic Solution, Atropine Sulphate Injection
Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 7, 2026, 6:45 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Effects of Low Dose Atropine on Choroidal Thickness

NCT03544827
View directory record Official record
Conditions
Myopia
Interventions
Atropine
Drug
Lead sponsor
State University of New York College of Optometry
Other
Eligibility
18 Years to 35 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Sep 7, 2026, 6:45 PM EDT
Completed Not applicable Interventional Results available

Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation

NCT01191398
View directory record Official record
Conditions
Sialorrhea
Interventions
Atropine (0.01mg/kg), Glycopyrrolate (0.01mg/kg), Normal saline 0.9%
Drug
Lead sponsor
Craig J. Huang
Other
Eligibility
6 Months to 18 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Sep 7, 2026, 6:45 PM EDT
Terminated Phase 3 Interventional

Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression

NCT03942419
View directory record Official record
Conditions
Myopia
Interventions
Atropine 0.1% Ophthalmic Solution, Atropine 0.01% Ophthalmic Solution, Placebo Ophthalmic Solution
Drug
Lead sponsor
Eyenovia Inc.
Industry
Eligibility
3 Years to 12 Years
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
18
States / cities
Birmingham, Alabama • Glendale, Arizona • Azusa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2025 · Synced Sep 7, 2026, 6:45 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Changes in Eye Shape With Myopia Management Interventions

NCT06450132
View directory record Official record
Conditions
Myopia
Interventions
Atropine Ophthalmic, MiSight 1-day disposable contact lenses
Drug · Device
Lead sponsor
Ohio State University
Other
Eligibility
21 Years to 30 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 7, 2026, 6:45 PM EDT
Not listed Phase 2 Interventional

StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study

NCT02082054
View directory record Official record
Conditions
Rhinitis, Seasonal, Allergic
Interventions
PSE 120 mg, CM 8 mg, Atr 0.36 mg, PSE 120 mg, CM 8 mg, Atr 0.24 mg, PSE 120 mg, CM 8 mg, Atr 0.12 mg, PSE 120 mg, CM 8 mg, Atropine 0.24 mg
Drug
Lead sponsor
Magna Pharmaceuticals, Inc.
Industry
Eligibility
12 Years to 60 Years
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
4
States / cities
Stockbridge, Georgia • Louisville, Kentucky • Charleston, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated May 29, 2014 · Synced Sep 7, 2026, 6:45 PM EDT
Completed Phase 4 Interventional Results available

Heart Rate Response to Atropine Doses Less Than 0.1mg IV to Anesthetized Infants

NCT01819064
View directory record Official record
Conditions
Bradycardia, Arrhythmias
Interventions
Atropine
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
1 Day to 2 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 5, 2023 · Synced Sep 7, 2026, 6:45 PM EDT
Completed Not applicable Interventional Results available

Atropine in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

NCT02927223
View directory record Official record
Conditions
Catecholaminergic Polymorphic Ventricular Tachycardia
Interventions
Atropine, Exercise treadmill test
Drug · Procedure
Lead sponsor
Vanderbilt University
Other
Eligibility
6 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 27, 2020 · Synced Sep 7, 2026, 6:45 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

NMBA Reversal and Postoperative Urinary Retention

NCT06948409
View directory record Official record
Conditions
Neuromuscular Blocking Agents, Urinary Retention After Procedure, Urinary Retention Postoperative, Neuromuscular Blockade Reversal Agent, Neuromuscular Blockade, Costs, Atropine, Sugammadex, Glycopyrrolate, Neostigmine, Anesthesia
Interventions
Choice of reversal agent (sugammadex or neostigmine [with muscaranic antagonist])
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
70,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Sep 7, 2026, 6:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sublingual Atropine Bioequivalence by Route of Administration (SABER)

NCT06366087
View directory record Official record
Conditions
Atropine Bioequivalence
Interventions
Atropine Sulfate Ophthalmic Solution USP, 1%, Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL)
Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 26, 2026 · Synced Sep 7, 2026, 6:45 PM EDT
Completed Phase 3 Interventional

Occlusion Versus Pharmacologic Therapy for Moderate Amblyopia

NCT00000170
View directory record Official record
Conditions
Amblyopia
Interventions
Atropine, Eye Patch
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
Up to 6 Years
Enrollment
419 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 5, 2014 · Synced Sep 7, 2026, 6:45 PM EDT
Not listed Phase 2 Interventional

Low Dose Atropine for Symptomatic Vitreous Floaters

NCT06174935
View directory record Official record
Conditions
Vitreous Floaters
Interventions
0.01% atropine ophthalmic drop
Drug
Lead sponsor
Jeanette Du
Other
Eligibility
19 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Reston, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 17, 2023 · Synced Sep 7, 2026, 6:45 PM EDT
Completed Phase 3 Interventional Results available

Trial Comparing Patching Versus Atropine for Amblyopia in 7 to < 13 Year Olds

NCT00315328
View directory record Official record
Conditions
Amblyopia
Interventions
Atropine, Patching, Near activities
Drug · Device · Procedure
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
7 Years to 12 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 23, 2016 · Synced Sep 7, 2026, 6:45 PM EDT
Terminated Phase 4 Interventional Results available

Use of Hyoscyamine Versus Tamsulosin for Management of Ureteral Stent Irritation

NCT03750656
View directory record Official record
Conditions
Lower Urinary Tract Symptoms
Interventions
Hyoscyamine, Tamsulosin
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2024 · Synced Sep 7, 2026, 6:45 PM EDT